Mesoblast Reports Q3 FY2026 Financial Results and Reaches Recruitment Target in Phase 3 CLBP Trial

Mesoblast Limited reported financial and operational results for the third fiscal quarter ended March 31, 2026. The company achieved RYONCIL net revenues of $30.3 million for the quarter, with gross sales of $35.3 million, bringing total revenue since launch to nearly $100 million. Net operating cash spend significantly improved to $4.1 million, supported by $34.6 million in customer receipts. As of March 31, 2026, Mesoblast held $122 million in cash and has approximately 41.8 quarters of funding available. Operationally, Mesoblast reached its patient recruitment target for the pivotal Phase 3 trial of rexlemestrocel-L in chronic low back pain (CLBP). The FDA cleared a trial for RYONCIL label extension in adults with SR-aGvHD and granted IND clearance for a registrational trial in Duchenne’s muscular dystrophy (DMD). Additionally, the company acquired an exclusive worldwide license for a CAR technology platform to enhance its mesenchymal stromal cell (MSC) products. Mesoblast also restructured its debt, drawing $75 million from a new $125 million credit facility to repay existing senior debt.